Aperio Group LLC purchased a new stake in Spark Therapeutics Inc (NASDAQ:ONCE) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 3,074 shares of the biotechnology company’s stock, valued at approximately $274,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Ameritas Investment Partners Inc. boosted its holdings in shares of Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Spark Therapeutics in the second quarter valued at approximately $143,000. BNP Paribas Arbitrage SA boosted its holdings in shares of Spark Therapeutics by 530.1% in the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 2,449 shares during the period. Pacad Investment Ltd. boosted its holdings in shares of Spark Therapeutics by 75.0% in the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 1,500 shares during the period. Finally, First Trust Advisors LP purchased a new stake in shares of Spark Therapeutics in the third quarter valued at approximately $615,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

In other news, insider Daniel Faga sold 1,500 shares of the stock in a transaction on Tuesday, September 19th. The stock was sold at an average price of $85.00, for a total transaction of $127,500.00. Following the completion of the sale, the insider now owns 1,500 shares in the company, valued at approximately $127,500. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Barge Joseph La sold 5,500 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $81.00, for a total value of $445,500.00. Following the sale, the insider now owns 10,825 shares of the company’s stock, valued at approximately $876,825. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,078,309 shares of company stock valued at $90,648,345. Company insiders own 7.30% of the company’s stock.

Shares of Spark Therapeutics Inc (ONCE) opened at $71.79 on Tuesday. Spark Therapeutics Inc has a twelve month low of $47.03 and a twelve month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The business had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $1.40 million. During the same quarter in the prior year, the company posted ($1.07) EPS. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. equities research analysts forecast that Spark Therapeutics Inc will post -7.6 EPS for the current year.

A number of analysts have weighed in on ONCE shares. Jefferies Group LLC restated a “buy” rating and set a $95.00 target price on shares of Spark Therapeutics in a report on Tuesday, October 10th. SunTrust Banks, Inc. set a $101.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, October 16th. BMO Capital Markets restated a “buy” rating and set a $101.00 target price on shares of Spark Therapeutics in a report on Wednesday, November 15th. Cowen Inc restated a “buy” rating and set a $95.00 target price on shares of Spark Therapeutics in a report on Tuesday, October 10th. Finally, Royal Bank Of Canada lowered their target price on Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating for the company in a report on Wednesday, November 8th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. Spark Therapeutics presently has an average rating of “Buy” and an average target price of $90.36.

TRADEMARK VIOLATION NOTICE: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/11/28/aperio-group-llc-purchases-shares-of-3074-spark-therapeutics-inc-once.html.

Spark Therapeutics Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Stock Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related stocks with our FREE daily email newsletter.